Sientra (NASDAQ:SIEN) Downgraded by Zacks Investment Research to Hold
According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
Other equities analysts have also issued reports about the company. Maxim Group reissued a buy rating and set a $12.00 price target (down from $16.00) on shares of Sientra in a research note on Friday, August 9th. Stephens set a $16.00 price target on Sientra and gave the company a buy rating in a report on Friday, August 9th. BidaskClub raised Sientra from a sell rating to a hold rating in a research note on Thursday, October 10th. William Blair raised Sientra from a market perform rating to an outperform rating in a report on Tuesday, November 5th. Finally, Canaccord Genuity set a $13.00 target price on Sientra and gave the company a buy rating in a research report on Tuesday, September 24th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $15.06.
Sientra (NASDAQ:SIEN) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported ($0.45) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.02. Sientra had a negative return on equity of 122.95% and a negative net margin of 143.76%. The firm had revenue of $22.41 million during the quarter, compared to analyst estimates of $20.05 million. During the same quarter last year, the business posted ($0.72) earnings per share. The business’s quarterly revenue was up 32.8% compared to the same quarter last year. As a group, analysts expect that Sientra will post -1.94 EPS for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC raised its position in Sientra by 97,855.6% during the third quarter. Millennium Management LLC now owns 3,242,332 shares of the medical instruments supplier’s stock valued at $21,010,000 after purchasing an additional 3,239,022 shares during the period. UBS Group AG increased its position in shares of Sientra by 37.9% during the 2nd quarter. UBS Group AG now owns 2,657,863 shares of the medical instruments supplier’s stock valued at $16,372,000 after purchasing an additional 730,475 shares during the last quarter. Vanguard Group Inc. raised its holdings in Sientra by 64.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,857,953 shares of the medical instruments supplier’s stock valued at $11,445,000 after buying an additional 727,906 shares during the period. BlackRock Inc. raised its holdings in Sientra by 11.7% during the 2nd quarter. BlackRock Inc. now owns 1,777,741 shares of the medical instruments supplier’s stock valued at $10,950,000 after buying an additional 185,695 shares during the period. Finally, Bamco Inc. NY lifted its position in Sientra by 4.4% in the second quarter. Bamco Inc. NY now owns 1,476,000 shares of the medical instruments supplier’s stock worth $9,092,000 after buying an additional 61,700 shares during the last quarter. Institutional investors own 89.76% of the company’s stock.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Recommended Story: Call Option
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.